Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 2Colorectal Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Myelodysplastic Syndromes 1Mouth Neoplasms 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Acute 1Erdheim-Chester Disease 1Endocrine Gland Neoplasms 1Disease Progression 1Colonic Neoplasms 1Castleman Disease 1Carcinoma, Transitional Cell 1Cancer That is Associated With a Chronic Viral Infection 1Breast Neoplasms 1

Interventions

Sirolimus 2temsirolimus 1carbon-11 acetate 1Valproic Acid 1Respiratory Function Tests 1Phlebotomy 1Immunoglobulin G 1Imatinib Mesylate 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Valproic Acid × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡